Job Opportunities API

The Public Ledger of Openings

← Back to the ledger

Scientist II - Biology

Olema Oncology
CompanyOlema Oncology
CategoryScience & Research
LocationSan Francisco
RemoteOn-site (inferred)
EmploymentNot stated
LevelNot stated
SalaryNot stated by the employer
Posted15 Jun 2026
Last verified3 Aug 2026
SourceEmployer ATS (greenhouse)
Applications are handled by the employer, not by us.Apply on the employer's site →
Description
Olema Oncology is  a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with  breast cancer  and beyond.   It’s  an exciting time to be part of Team Olema ,  with   our transfor mation into a fully   integrated oncology company well underway ,  t op-line data from our lead program expected  later  this  year ,   and our first potential commercial launch on the horizon. Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in the fall which, if successful, could lead to our first potential approval and commercial launch in 2027. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant has the potential to transform the metastatic breast cancer treatment paradigm and access a $15 billion global market opportunity. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently reported encouraging Phase 1 monotherapy data from this program across multiple solid tumor types and are advancing patient enrollment in the ongoing combination arms in MBC. Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and a passionate team dedicated to helping the patients we serve feel better, longer. We possess a deep commitment to our shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution.  Team Olema is made up of nimble self-starters who bring consistency in their quest for the extraordinary every single day. If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together –  for  our patients, for your career,  and  for  what’s  beyond . About the role >>>  Scientist II - Biology The Role:   Olema Oncology is currently seeking a talented and innovative  Scientist II to join the Research Biology team as a screening specialist. Responsibilities of this position will include developing biology specific strategies for early-stage research projects, development and execution of biochemical and/or cellular phenotypic screening assays of new drug candidates, programming and use of liquid handler automation systems, as well as mentorship of junior scientists within the team. You will be responsible for conducting experiments to generate&nbsp